Feb 29, 2016 7:03 am EST Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Systemic AAV Phase 1/2 Clinical Study With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA)
Feb 24, 2016 9:36 am EST Abeona Therapeutics, Inc. to Present on CRISPR/CAS9 Technology Platform Progress at CRISPR Precision Gene Editing Congress
Feb 9, 2016 9:17 am EST Abeona Therapeutics to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
Feb 4, 2016 9:28 am EST Abeona Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
Jan 11, 2016 9:03 am EST Abeona Therapeutics Announces Initial European Regulatory Approvals for Phase 1/2 Gene Therapy Clinical Studies for Patients With Sanfilippo Syndromes Type A (MPS IIIA) and Type B (MPS IIIB)
Dec 1, 2015 9:03 am EST Abeona Therapeutics to Present at Piper Jaffray 27th Annual Healthcare Conference
Nov 18, 2015 9:03 am EST Abeona Therapeutics to Present at Jefferies 2015 Global Healthcare Conference
Nov 17, 2015 9:03 am EST Abeona Therapeutics Reports Financial Results and Highlights for Third Quarter 2015
Oct 6, 2015 9:03 am EDT Abeona Therapeutics Announces License for Next Generation AAV Delivery Vector for Fanconi Anemia and Rare Blood Disease Platform
